Clinical trials: Diabetes, Type II
Diabetes Mellitus, Type 2
An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes
The purpose of this study is to identify specific patient, physician, and health system related factors associated with the progression to a more intensive regimen from initial insulin therapy for patients with type 2 diabetes.
- Trial name
- MOSAIc (NCT01400971)
- Where
- 153 sites in United States, Argentina and 17 more
- Volunteers
- 4,299 people
- Sponsor
- Eli Lilly and Company
Obesity
Study of Impact of Behavioral Intervention- Exercise, Nutrition, Education- on Body Mass Index (BMI)
This study will evaluate the impact a behavioral intervention can have on BMI. The researchers anticipate the intervention group will experience a decrease in BMI of approximately five points.
- Trial name
- NCT00132132
- Testing
- Behavioral education program
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Steward St. Elizabeth's Medical Center of Boston, Inc.
Diabetes
A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone
This clincial trial is evaluating if the co-administration of saxagliptin and dapagliflozin, in addition to metformin, results in better glycemic control, as measured by HbA1c, over a treatment period of 52 weeks, compared to the…
- Trial name
- NCT02419612
- Testing
- Saxagliptin, Dapagliflozin, Glimepiride
- Where
- 84 sites in United States, Czechia and 8 more
- Volunteers
- 444 people
- Sponsor
- AstraZeneca
Interaction, Adverse Herb-Drug, Diabetes Mellitus, Type 2
Clinical Evaluation of the Pharmacokinetic Goldenseal-Metformin Interaction in Diabetic Patients
Supplements containing goldenseal, a perennial herb native to North America, have consistently ranked among the top 20 highest selling natural products throughout the last decade.
- Trial name
- NCT05081583
- Testing
- Midazolam Hcl 1Mg/Ml Inj, Goldenseal (Hydrastis canadensis)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Washington State University
Type 2 Diabetes Mellitus
Pioglitazone Tablets Specified Drug-use Survey <Survey on Glycemic Control in Type 2 Diabetic Patients With a History of Cerebral Infarction>
The purpose of this survey is to evaluate the effects on glycemic control and to evaluate the safety of long-term use of pioglitazone tablets (Actos Tablets) in type 2 diabetic patients with inadequate glycemic control and a…
- Trial name
- NCT02181842
- Testing
- Pioglitazone
- Volunteers
- 246 people
- Sponsor
- Takeda
Type 1 Diabetes, Type 2 Diabetes
Adult Accuracy Study of the Enlite 3 Glucose Sensor
The purpose of this study is to demonstrate the performance of the Enlite 3 Sensor over 168 hours (7 days) when inserted in the abdomen and used with the Guardian Mobile App and 640G Pump in subjects aged 14-75 years with type 1…
- Trial name
- E3 (NCT02246582)
- Testing
- Enlite 3, Guardian Mobile App, 640G Insulin Pump
- Where
- 6 sites in United States
- Volunteers
- 118 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 2
4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)
The objective of this trial is to evaluate the pharmacodynamics, pharmacokinetics, safety, and tolerability of once daily oral administration of BI 10773 administered for 28 days in Japanese patients with T2DM.
- Trial name
- NCT00885118
- Testing
- BI 10773
- Where
- 5 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Boehringer Ingelheim
Sub-optimal Vitamin D Status, Pre-diabetes
Effect of Vitamin D3 Supplementation on Insulin Resistance- The DIR Study
Insulin resistance is a state where the body does not respond as it should to the insulin it produces. Individuals who are insulin resistant are at increased risk of both heart disease and type 2 diabetes; importantly, diabetes…
- Conditions
- Sub-optimal Vitamin D Status, Pre-diabetes, Insulin Resistance
- Trial name
- NCT01889810
- Testing
- Vitamin D3 supplementation
- Where
- United Kingdom
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Queen's University, Belfast
Diabetes Mellitus, Type 2
Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes
to demonstrate the efficacy of inhaled Technosphere/Insulin in combination with metformin versus combination metformin and a secretagogue
- Trial name
- NCT00332488
- Testing
- Technosphere Insulin, Metformin & Secretagogues, Technosphere Insulin & Metformin
- Where
- 120 sites in United States, Argentina and 9 more
- Volunteers
- 547 people
- Sponsor
- Mannkind Corporation
Diabetes Mellitus, Type 2, Adult
Effects of Once and Twice Daily Dosing Regimen of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040)
This is a Phase 1 randomized, double-blind, sponsor open, 4 arm, 2 way cross-over study using 2 cohorts. The objective of the study is to evaluate the pharmacodynamics (PD) effects and the pharmacokinetic (PK) of single day…
- Trial name
- NCT01054300
- Testing
- Ertugliflozin 2 mg single dose, Ertugliflozin 2 mg split into twice daily, Ertugliflozin 4 mg single dose
- Volunteers
- 52 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Safety and Tolerability Study of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 Diabetes
This is a Phase 2a study designed to assess the safety and tolerability of MEDI0382 titrated up to a dose level of 100, 200 or 300 µg from 50 µg vs Placebo across 48 days in Japanese subjects.
- Trial name
- NCT03645421
- Testing
- MEDI0382 100 μg, MEDI0382 200 μg, MEDI0382 300 μg
- Where
- 5 sites in Japan
- Volunteers
- 61 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) as monotherapy or in combination with oral antihyperglycaemic agent in patients with type 2 Diabetes for 52 weeks administration.
- Trial name
- NCT01301833
- Testing
- teneligliptin, glinide, biguanide
- Where
- Japan
- Volunteers
- 462 people
- Sponsor
- Tanabe Pharma Corporation
Type 2 Diabetes (T2D)
Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)
This study will test the safety and tolerability of omarigliptin. It is hypothesized that administration of once-weekly omarigliptin in obese but otherwise healthy participants, and in obese participants with Type 2 diabetes…
- Trial name
- NCT01088711
- Testing
- Omarigliptin
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
This is a multi-center, randomized, open-label, parallel-group comparative, exploratory study to evaluate the effect of trelagliptin administered at a dose of 100 mg once weekly or alogliptin administered at a dose of 25 mg once…
- Trial name
- TRACK (NCT02771093)
- Testing
- Trelagliptin, Alogliptin
- Where
- Japan
- Volunteers
- 27 people
- Sponsor
- Takeda
Type 2 Diabetes, Inpatient Hyperglycemia
Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery
High blood glucose levels in surgical patients with diabetes are associated with increased risk of medical complications and death.
- Trial name
- RABBIT 2-SX (NCT00596687)
- Testing
- Insulin glargine, Regular insulin, Insulin glulisine
- Where
- 2 sites in United States
- Volunteers
- 234 people
- Sponsor
- Emory University
Diabetes Mellitus Type 2
Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Oral Bedtime Doses of ORMD-0801 in Adult Patients With Type 2 Diabetes Mellitus (T2DM)
The purpose of this study is to test the safety and pharmacodynamics of an oral formulation of insulin in subjects with Type 2 Diabetes.
- Trial name
- NCT01889667
- Testing
- ORMD-0801 Dose # 1, ORMD-0801 Dose # 2
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Oramed, Ltd.
Obese, Diabetes Mellitus, Type 2
Investigating Effects of BOTOX on Weight Loss and Glucose Tolerance in Obese, Type 2 Diabetic Subjects
The investigators will recruit obese subjects with pre-diabetes or type 2 diabetes for the proposed clinical study for 5 visits.
- Trial name
- NCT03991299
- Testing
- Botox 200 UNT Injection
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Vanderbilt University Medical Center
Obesity, Hypertension
Multicenter Endoscopic Sleeve Gastrectomy (ESG) Trial (MERIT Trial)
Endoscopic Sleeve Gastroplasty (ESG) is an endoscopic minimally invasive weight loss procedure where a commercially available, FDA approved, full-thickness endoscopic suturing device (Overstitch; Apollo Endosurgery, Austin, TX)…
- Conditions
- Obesity, Hypertension, Diabetes Mellitus, Type 2
- Trial name
- NCT03406975
- Testing
- Overstitch Endoscopic Suture System, Lifestyle Intervention
- Where
- 9 sites in United States
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Type 2 Diabetes Mellitus
A Study of the Effects of Co-Administration of Sitagliptin (MK-0431) and Metformin on Incretin Hormone Concentrations (MK-0431-110)
This study will assess the effects of sitagliptin and metformin alone and after co-administration on incretin hormone concentrations in patients with Type 2 diabetes.
- Trial name
- NCT00830076
- Testing
- sitagliptin phosphate, metformin hydrochloride
- Volunteers
- 18 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment
The purpose of this study is to compare insulin peglispro (LY2605541) to insulin glargine in Asian insulin naïve participants who have been treated with oral anti hyperglycemia medications.
- Trial name
- NCT01894568
- Testing
- Insulin Peglispro, Insulin Glargine, Oral Antihyperglycemic Medications (OAMs)
- Where
- 31 sites in Japan, South Korea and 1 more
- Volunteers
- 388 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.